Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses

NCT00603798 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00603798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Six Weeks of Treatment With Imiquimod Creams for Actinic Keratoses
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
July 31, 2008
Enrollment
490 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis